Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised,placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised,placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

摘要：
本文献已被 SpringerLink 等数据库收录！